Outcomes of critically ill patients with cirrhosis admitted to intensive care: an important perspective from the non-transplant setting.

Sam J Thomson (1) , Carl P Moran (1) , Matthew L Cowan (2) , Saif A Musa (1) , Richard Beale (3) , David Treacher (1) , Mark Hamilton (4) , Michael Grounds (1) , Tony M Rahman (1)

1 Hepatology & General Intensive Care
2 Hepatology
3 General Intensive Care
4 General Intensive Care

Background: Hospital admissions for cirrhosis are increasing in the UK, leading to increased pressure on intensive care (ICU) services. Outcome data for patients admitted to ICU are currently limited to transplant centre reports, with mortality rates exceeding 70%. These tertiary reports could fuel a negative bias when patients with cirrhosis are reviewed for ICU admission in secondary care. Aims: To determine whether disease severity and mortality rates in non-transplant general ICU are less severe than those reported by tertiary datasets. Methods: A prospective dual-centre non-transplant ICU study. Admissions were screened for cirrhosis, and physiological and biochemical data were collected. Disease specific and critical illness scoring systems were evaluated. Results: Cirrhosis was present in 137/4198 (3.3%) of ICU admissions. ICU and hospital mortality were 38% and 47%, respectively; median age 50 [43-59] years, 68% male, 72% alcoholic cirrhosis, median CPS 10 [8-11], MELD 18 [12-24], APACHE II 16 [13-22]. Conclusion: Mortality rates and disease staging were notably lower than in the published literature, suggesting that patients have a more favourable outlook than previously considered. Transplant centre data should therefore be interpreted with caution when evaluating the merits of intensive care admission for patients in general secondary care ICUs.

Mots clés: Medicine

Sam J Thomson, Carl P Moran, Matthew L Cowan, Saif A Musa, Richard Beale, et al.. Outcomes of critically ill patients with cirrhosis admitted to intensive care: an important perspective from the non-transplant setting.. Alimentary Pharmacology and Therapeutics, 2010, 32 (2), pp.233. ⟨10.1111/j.1365-2036.2010.04341.x⟩. ⟨hal-00552567⟩